Search Results - "Biemond, Bart"

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome by Grob, Tim, Al Hinai, Adil S.A., Sanders, Mathijs A., Kavelaars, François G., Rijken, Melissa, Gradowska, Patrycja L., Biemond, Bart J., Breems, Dimitri A., Maertens, Johan, van Marwijk Kooy, Marinus, Pabst, Thomas, de Weerdt, Okke, Ossenkoppele, Gert J., van de Loosdrecht, Arjan A., Huls, Gerwin A., Cornelissen, Jan J., Beverloo, H. Berna, Löwenberg, Bob, Jongen-Lavrencic, Mojca, Valk, Peter J.M.

“…Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact…”
Get full text

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients by Huls, Gerwin, Chitu, Dana A., Havelange, Violaine, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A., Biemond, Bart J., Sinnige, Harm, Hodossy, Beata, Graux, Carlos, Kooy, Rien van Marwijk, de Weerdt, Okke, Breems, Dimitri, Klein, Saskia, Kuball, Jürgen, Deeren, Dries, Terpstra, Wim, Vekemans, Marie-Christiane, Ossenkoppele, Gert J., Vellenga, Edo, Löwenberg, Bob

“…The prevention of relapse is the major therapeutic challenge in older patients with acute myeloid leukemia (AML) who have obtained a complete remission (CR) on…”
Get full text

Withholding transfusion therapy in children with sickle cell disease with abnormal transcranial Doppler and normal magnetic resonance angiography: a retrospective analysis by De Ligt, Lydian A, Fijnvandraat, Karin, Biemond, Bart J, Heijboer, Harriet

Get full text

Prevalence of autoimmune diseases in patients with sickle cell disease: a single center retrospective analysis by Tang, Man Wai, Nur, Erfan, Van Tuijn, Charlotte F J, Biemond, Bart J

Get full text

Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19) by Nur, Erfan, Gaartman, Aafke E., Tuijn, Charlotte F. J., Tang, Man Wai, Biemond, Bart J.

Get full text

Cytarabine Dose for Acute Myeloid Leukemia by Löwenberg, Bob, Pabst, Thomas, Vellenga, Edo, van Putten, Wim, Schouten, Harry C, Graux, Carlos, Ferrant, Augustin, Sonneveld, Pieter, Biemond, Bart J, Gratwohl, Alois, de Greef, Georgine E, Verdonck, Leo F, Schaafsma, Martijn R, Gregor, Michael, Theobald, Matthias, Schanz, Urs, Maertens, Johan, Ossenkoppele, Gert J

“…High-dose cytarabine is up to 30 times the standard dose of this drug. Although more effective, the higher dose is more toxic. In this study, an intermediate…”
Get full text

Effect of allogeneic hematopoietic stem cell transplantation on sickle cell disease‐related organ complications: A systematic review and meta‐analysis by Dovern, Elisabeth, Aydin, Mesire, DeBaun, Michael R., Alizade, Komeil, Biemond, Bart J., Nur, Erfan

“…Sickle cell disease (SCD)‐related organ complications are a major cause of morbidity and mortality in patients with SCD. We sought to assess whether…”
Get full text

ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning by Aydin, Mesire, de Leeuw, David C, Rutten, Caroline E, Visser, Otto J, Tang, Man Wai, van Roessel, Cinthy, Janssen, Jeroen J W, Biemond, Bart J, van de Loosdrecht, Arjan A, Hazenberg, Mette D, Meijer, Ellen, Nur, Erfan

“…Graft-versus-host disease (GvHD) is a serious complication of allogeneic haematopoietic stem cell transplantation (HSCT). Both anti-thymocyte globulin (ATG)…”
Get full text

Assessment of functional shunting in patients with sickle cell disease by Afzali-Hashemi, Liza, Václavů, Lena, Wood, John C, Biemond, Bart J, Nederveen, Aart J, Mutsaerts, Henk J M M, Schrantee, Anouk

“…Silent cerebral infarcts (SCI) are common in patients with sickle cell disease (SCD) and are thought to be caused by a mismatch between oxygen delivery and…”
Get full text

Platelet Transfusion in Patients with Thrombocytopenia. Reply by van Baarle, Floor L F, Biemond, Bart J, Vlaar, Alexander P J

Get full text

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia by Löwenberg, Bob, Ossenkoppele, Gert J, van Putten, Wim, Schouten, Harry C, Graux, Carlos, Ferrant, Augustin, Sonneveld, Pieter, Maertens, Johan, Jongen-Lavrencic, Mojca, von Lilienfeld-Toal, Marie, Biemond, Bart J, Vellenga, Edo, Kooy, Marinus van Marwijk, Verdonck, Leo F, Beck, Joachim, Döhner, Hartmut, Gratwohl, Alois, Pabst, Thomas, Verhoef, Gregor

“…Patients with acute myeloid leukemia (AML) who were more than 60 years of age received treatment to induce a complete remission that consisted of cytarabine…”
Get full text

Comparative Analysis of Blood T 2 Values Measured by T 2 -TRIR and TRUST by Baas, Koen P A, Coolen, Bram F, Petersen, Esben T, Biemond, Bart J, Strijkers, Gustav J, Nederveen, Aart J

“…Venous blood oxygenation (Yv), which can be derived from venous blood T (T b), combined with oxygen-extraction fraction (OEF) and cerebral metabolic rate of…”
Get full text

Macular neurodegenerative and vascular changes on OCTA in sickle cell disease are not related to its ocular and systemic complications by Brandsen, Rajani P, Biemond, Bart J, Nasim, Gulsum Z, Nur, Erfan, Schlingemann, Reinier O, Diederen, Roselie M H

“…To evaluate macular abnormalities in sickle cell disease (SCD) with OCT-Angiography (OCTA) and to determine associations with sickle cell retinopathy (SCR) and…”
Get full text

Comparative Analysis of Blood T2 Values Measured by T2‐TRIR and TRUST by Baas, Koen P. A., Coolen, Bram F., Petersen, Esben T., Biemond, Bart J., Strijkers, Gustav J., Nederveen, Aart J.

“…Background Venous blood oxygenation (Yv), which can be derived from venous blood T2 (T2b), combined with oxygen‐extraction fraction (OEF) and cerebral…”
Get full text

Hemodynamic provocation with acetazolamide shows impaired cerebrovascular reserve in adults with sickle cell disease by Václavů, Lena, Meynart, Benoit N, Mutsaerts, Henri J M M, Petersen, Esben Thade, Majoie, Charles B L M, VanBavel, Ed T, Wood, John C, Nederveen, Aart J, Biemond, Bart J

“…Sickle cell disease is characterized by chronic hemolytic anemia and vascular inflammation, which can diminish the vasodilatory capacity of the small…”
Get full text

Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target by Ligt, Lydian A., Gaartman, Aafke E., Biemond, Bart J., Fijnvandraat, Karin, Bruggen, Robin, Nur, Erfan

“…Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia and recurrent microvascular occlusions, resulting in acute…”
Get full text

Limited value of the D‐dimer based YEARS algorithm to rule out pulmonary embolism in sickle cell disease and sickle cell trait by Gaartman, Aafke E., Strijdhorst, Anniek, Es, Nick, Tang, Man Wai, Heijmans, Jarom, Biemond, Bart J., Nur, Erfan

Get full text

Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease by VAN BEERS, Eduard J, SCHAAP, Marianne C. L, BERCKMANS, René J, NIEUWLAND, Rienk, STURK, Augueste, VAN DOORMAAL, Frederiek F, MEIJERS, Joost C. M, BIEMOND, Bart J

“…Sickle cell disease is characterized by a hypercoagulable state as a result of multiple factors, including chronic hemolysis and circulating cell-derived…”
Get full text

Venous Blood Oxygenation Measurements Using TRUST and T2‐TRIR MRI During Hypoxic and Hypercapnic Gas Challenges by Baas, Koen P. A., Vu, Chau, Shen, Jian, Coolen, Bram F., Biemond, Bart J., Strijkers, Gustav J., Wood, John C., Nederveen, Aart J.

“…Background Oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen (CMRO2) may serve as biomarkers in several diseases. OEF and CMRO2 can be…”
Get full text

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label study by Dijk, Myrthe J., Rab, Minke A. E., Oirschot, Brigitte A., Bos, Jennifer, Derichs, Cleo, Rijneveld, Anita W., Cnossen, Marjon H., Nur, Erfan, Biemond, Bart J., Bartels, Marije, Jans, Judith J. M., Solinge, Wouter W., Schutgens, Roger E. G., Wijk, Richard, Beers, Eduard J.

Get full text